試す 金 - 無料
The Nano Approach Of Medicines
Bio Spectrum
|February 2018 ,Vol 16 Issue 05
Increase in adoption of novel nanomedicines products drives the market growth in India. Moreover, increase in the number of players and high adoption of innovative technologies further fuel the market growth. In addition, robust government initiative toward improvement of healthcare facilities through insurance schemes is anticipated to provide lucrative growth opportunities in the country. The nanomedicines market in India is expected to grow at the highest CAGR of 13.4% from 2016 to 2023.
Geographically, the market for nanomedicine is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Currently, North America accounts for the largest market share. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period of 2018-2023, owing to the improving research infrastructure in the region, improved purchasing power of patients, the rapid increase in geriatric population, and rising awareness regarding healthcare. China and India are to be foreseen as the growing nanomedicine markets in Asia.
The global nanomedicine market accounted for $111.9 billion in 2016, and is anticipated to reach $261.1 billion by 2023, registering a CAGR of 12.6 per cent from 2017 to 2023, according to a new report published by Allied Market Research.
A new report by Grand View Research, Inc. observed that the global nanomedicine market is anticipated to reach $ 350.8 billion by 2025. Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.
Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.
As per the World Health Organisation (WHO) factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.
このストーリーは、Bio Spectrum の February 2018 ,Vol 16 Issue 05 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
S&T Minister inaugurates Biotechnology Research and Innovation Council (BRIC) Secretariat
The Union Minister of (Independent State Charge) for Science and Technology (S&T) Dr Jitendra Singh recently inaugurated the Biotechnology Research and Innovation Council (BRIC) Secretariat by unveiling the inaugural curtain, marking the official opening of a new milestone in India's biotechnology journey.
1 min
February 2026
Bio Spectrum
US announces $50 B in awards to strengthen rural healthcare
The Centers for Medicare & Medicaid Services (CMS) has announced that all 50 states will receive awards under the Rural Health Transformation Program, a $50 billion initiative established under President Trump's Working Families Tax Cuts legislation (Public Law 119-21) to strengthen and modernise healthcare in rural communities across the country.
1 min
February 2026
Bio Spectrum
WHO unveils Traditional Medicine Global Library
At the second WHO Global Summit on Traditional Medicine, jointly organised with the Government of India, concluding recently in New Delhi, WHO unveiled the Traditional Medicine (TM) Global Library (GL), a first-of-its-kind digital platform consolidating 1.6 million resources on TM, from scientific studies to indigenous knowledge.
1 min
February 2026
Bio Spectrum
Telangana sets global ambition with Life Sciences Policy 2026-30 targeting $25 B investments
The Government of Telangana unveiled its Next-Gen Life Sciences Policy 2026-30 at the World Economic Forum Annual Meeting in Davos, signalling the State's intent to play a far more consequential role in shaping the future of global healthcare, advanced therapeutics, and sustainable bio-manufacturing.
1 min
February 2026
Bio Spectrum
WHO reveals major equity gaps in human genomics research
The World Health Organization (WHO) has published a new global analysis of human genomics in clinical research, covering more than three decades of studies registered between 1990 and 2024.
1 min
February 2026
Bio Spectrum
Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits
US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.
1 min
February 2026
Bio Spectrum
Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio
Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.
1 min
February 2026
Bio Spectrum
India & Australia develop precision nano-injection platform for breast cancer drug delivery
Researchers from the Indian Institute of Technology Madras (IIT-M), Monash University and Deakin University, Australia, have developed a cutting-edge nano-injection drug delivery platform that has the potential to make breast cancer treatment safer and more effective.
1 min
February 2026
Bio Spectrum
Agilent opens India Refurbishment Centre in Manesar
Agilent Technologies Inc., a global leader in life sciences, diagnostics, and applied chemical markets, has announced the inauguration of its India Refurbishment Centre at its LEED Platinum-certified facility in Manesar, Haryana.
1 min
February 2026
Bio Spectrum
Yashoda Medicity appoints Dr Rajinder Kumar as Unit Head, Department of Neurosurgery
Yashoda Medicity, one of the leading hospitals in the Delhi NCR, has appointed Prof. Dr Rajinder Kumar as Principal Director & Unit Head, Neurosurgery at the Yashoda Institute of Neurosciences.
1 min
February 2026
Translate
Change font size
